 | • レポートコード：D0GIR-00684 • 出版社/出版日：GlobalInfoResearch / 2020年9月18日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、胃腸膵神経内分泌腫瘍治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。胃腸膵神経内分泌腫瘍治療の種類別市場規模（化学療法、ペプチド受容体放射性核種療法、その他）、用途別市場規模（病院、クリニック、外来手術センター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Novartis、Tarveda Therapeutics、Teva Pharmaceuticals、Pfizer、Exelixis, Inc.、Fresenius Kabi、Hutchison China MediTech Limited、Sun Pharma ・地域別グローバル市場分析 2015年-2020年 ・胃腸膵神経内分泌腫瘍治療の北米市場（アメリカ、カナダ、メキシコ） ・胃腸膵神経内分泌腫瘍治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・胃腸膵神経内分泌腫瘍治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・胃腸膵神経内分泌腫瘍治療の南米市場（ブラジル、アルゼンチン） ・胃腸膵神経内分泌腫瘍治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：化学療法、ペプチド受容体放射性核種療法、その他 ・用途別分析：病院、クリニック、外来手術センター、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics sales will be xx in 2020 from Gastroenteropancreatic Neuroendocrine Tumor Therapeutics million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Gastroenteropancreatic Neuroendocrine Tumor Therapeutics and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market has been segmented into:
Chemotherapy
Peptide-Receptor Radionuclide Therapy
Others
By Application, Gastroenteropancreatic Neuroendocrine Tumor Therapeutics has been segmented into:
Hospitals
Clinics
Ambulatory Surgical Centers
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Gastroenteropancreatic Neuroendocrine Tumor Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market.
The report offers in-depth assessment of the growth and other aspects of the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share Analysis
Gastroenteropancreatic Neuroendocrine Tumor Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Gastroenteropancreatic Neuroendocrine Tumor Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics sales, revenue and market share for each player covered in this report.
The major players covered in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics are:
Novartis
Tarveda Therapeutics
Teva Pharmaceuticals
Pfizer
Exelixis, Inc.
Fresenius Kabi
Hutchison China MediTech Limited
Sun Pharma
Among other players domestic and global, Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Overview
1.1 Product Overview and Scope of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics
1.2 Classification of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Therapy
1.2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Therapy in 2019
1.2.3 Chemotherapy
1.2.4 Peptide-Receptor Radionuclide Therapy
1.2.5 Others
1.3 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market by End Users
1.3.1 Overview: Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market by Regions
1.4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Industry Impact
1.5.1 COVID-19 Potential Implications for the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Gastroenteropancreatic Neuroendocrine Tumor Therapeutics
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Novartis SWOT Analysis
2.1.4 Novartis Product and Services
2.1.5 Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Tarveda Therapeutics
2.2.1 Tarveda Therapeutics Details
2.2.2 Tarveda Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Tarveda Therapeutics SWOT Analysis
2.2.4 Tarveda Therapeutics Product and Services
2.2.5 Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Teva Pharmaceuticals
2.3.1 Teva Pharmaceuticals Details
2.3.2 Teva Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Teva Pharmaceuticals SWOT Analysis
2.3.4 Teva Pharmaceuticals Product and Services
2.3.5 Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Pfizer SWOT Analysis
2.4.4 Pfizer Product and Services
2.4.5 Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Exelixis, Inc.
2.5.1 Exelixis, Inc. Details
2.5.2 Exelixis, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Exelixis, Inc. SWOT Analysis
2.5.4 Exelixis, Inc. Product and Services
2.5.5 Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Fresenius Kabi
2.6.1 Fresenius Kabi Details
2.6.2 Fresenius Kabi Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Fresenius Kabi SWOT Analysis
2.6.4 Fresenius Kabi Product and Services
2.6.5 Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 Hutchison China MediTech Limited
2.7.1 Hutchison China MediTech Limited Details
2.7.2 Hutchison China MediTech Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Hutchison China MediTech Limited SWOT Analysis
2.7.4 Hutchison China MediTech Limited Product and Services
2.7.5 Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 Sun Pharma
2.8.1 Sun Pharma Details
2.8.2 Sun Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Sun Pharma SWOT Analysis
2.8.4 Sun Pharma Product and Services
2.8.5 Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players Market Share
3.2.2 Top 10 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Market Share by Regions
4.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Countries
5.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Countries (2015-2020)
5.2 USA Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Countries
6.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Countries
7.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Countries (2015-2020)
7.2 China Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Countries
8.1 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Countries
9.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Market Share by Therapy (2015-2020)
10.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Forecast by Therapy (2019-2024)
10.3 Chemotherapy Revenue Growth Rate (2015-2025)
10.4 Peptide-Receptor Radionuclide Therapy Revenue Growth Rate (2015-2025)
10.5 Others Revenue Growth Rate (2015-2025)
11 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Segment by End Users
11.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by End Users (2015-2020)
11.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Forecast by End Users (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Ambulatory Surgical Centers Revenue Growth (2015-2020)
11.6 Others Revenue Growth (2015-2020)
12 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Forecast (2021-2025)
12.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Forecast (2021-2025)
12.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Novartis Corporate Information, Location and Competitors
Table 7. Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Major Business
Table 8. Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 9. Novartis SWOT Analysis
Table 10. Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions
Table 11. Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Tarveda Therapeutics Corporate Information, Location and Competitors
Table 13. Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Major Business
Table 14. Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Total Revenue (USD Million) (2018-2019)
Table 15. Tarveda Therapeutics SWOT Analysis
Table 16. Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions
Table 17. Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Teva Pharmaceuticals Corporate Information, Location and Competitors
Table 19. Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Major Business
Table 20. Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 21. Teva Pharmaceuticals SWOT Analysis
Table 22. Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions
Table 23. Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Pfizer Corporate Information, Location and Competitors
Table 25. Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Major Business
Table 26. Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 27. Pfizer SWOT Analysis
Table 28. Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions
Table 29. Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Exelixis, Inc. Corporate Information, Location and Competitors
Table 31. Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Major Business
Table 32. Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 33. Exelixis, Inc. SWOT Analysis
Table 34. Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions
Table 35. Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Fresenius Kabi Corporate Information, Location and Competitors
Table 37. Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Major Business
Table 38. Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 39. Fresenius Kabi SWOT Analysis
Table 40. Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions
Table 41. Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Hutchison China MediTech Limited Corporate Information, Location and Competitors
Table 43. Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Major Business
Table 44. Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 45. Hutchison China MediTech Limited SWOT Analysis
Table 46. Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions
Table 47. Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Sun Pharma Corporate Information, Location and Competitors
Table 49. Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Major Business
Table 50. Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Total Revenue (USD Million) (2017-2018)
Table 51. Sun Pharma SWOT Analysis
Table 52. Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product and Solutions
Table 53. Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 55. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Players (2015-2020)
Table 56. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 57. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Regions (2015-2020)
Table 58. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Countries (2015-2020)
Table 59. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Table 60. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 61. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 62. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Countries (2015-2020)
Table 63. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Table 64. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 65. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Table 66. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 67. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Type (2015-2020)
Table 68. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Forecast by Type (2021-2025)
Table 69. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Application (2015-2020)
Table 70. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Application (2015-2020)
Table 71. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Forecast by Application (2021-2025)
Table 72. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Picture
Figure 2. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Therapy in 2019
Figure 3. Chemotherapy Picture
Figure 4. Peptide-Receptor Radionuclide Therapy Picture
Figure 5. Others Picture
Figure 6. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by End Users in 2019
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Ambulatory Surgical Centers Picture
Figure 10. Others Picture
Figure 11. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 12. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Players in 2019
Figure 19. Global Top 5 Players Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share in 2019
Figure 20. Global Top 10 Players Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share in 2019
Figure 21. Key Players Market Share Trend
Figure 22. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 23. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 24. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Regions in 2018
Figure 25. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 26. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 28. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 29. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 30. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 31. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Countries in 2019
Figure 32. USA Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 33. Canada Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 34. Mexico Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 35. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 36. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Countries in 2019
Figure 37. Germany Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. UK Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. France Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 40. Russia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 41. Italy Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 43. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Countries in 2019
Figure 44. China Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. Japan Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. Korea Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 47. India Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 48. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 49. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 50. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Countries in 2019
Figure 51. Brazil Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 52. Argentina Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 53. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 54. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Countries in 2019
Figure 55. Saudi Arabia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. UAE Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 57. Egypt Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 58. South Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue and Growth Rate (2015-2020)
Figure 59. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Type (2015-2020)
Figure 60. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Type in 2019
Figure 61. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share Forecast by Type (2021-2025)
Figure 62. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 63. Global Peptide-Receptor Radionuclide Therapy Revenue Growth Rate (2015-2020)
Figure 64. Global Others Revenue Growth Rate (2015-2020)
Figure 65. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Application (2015-2020)
Figure 66. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Application in 2019
Figure 67. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share Forecast by Application (2021-2025)
Figure 68. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 69. Global Clinics Revenue Growth Rate (2015-2020)
Figure 70. Global Ambulatory Surgical Centers Revenue Growth Rate (2015-2020)
Figure 71. Global Others Revenue Growth Rate (2015-2020)
Figure 72. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 73. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 74. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 75. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Forecast (2021-2025)
Figure 76. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Forecast (2021-2025)
Figure 77. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Forecast (2021-2025)
Figure 78. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Forecast (2021-2025)
Figure 79. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Forecast (2021-2025)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
脳腫瘍療法の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Brain Tumor Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 10.0% in the forecast period of 2020 to 2025 and will expected to reach USD 1552.3 million by 2025, from USD 1060.2 million in 2019. The Brain Tumo…- 神経内分泌機能検査の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Neuroendocrine Function Test market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Neuroendocrine F…
- 腫瘍治療フィールド（TTFields）の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Tumor Treating Fields (TTFields) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Tumor Treati…
- 交流電場腫瘍治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Alternating Electric Field Tumor Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Al…
- 歯原性腫瘍の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Odontogenic Tumor market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Odontogenic Tumor market re…